Table 1.
Demographics and clinical characteristics of individuals with PAH in the EWAS
| UK PAH Cohort Median (25–75%) | ||
|---|---|---|
| Idiopathic/heritable PAH, n | 389/40 | |
| Age at sample | 51.27 (40.27–64.03) | |
| Sex, n | Female | 314 |
| Male | 115 | |
| WHO functional class, n | I | 8 |
| II | 76 | |
| III | 273 | |
| IV | 57 | |
| 6-min walk distance, m | 336.00 (230.75–414.25) | |
| Mean pulmonary artery pressure, mmHg | 54.00 (46.00–62.00) | |
| Mean pulmonary artery wedge pressure, mmHg | 10.00 (7.00–12.00) | |
| Mean right atrial pressure, mmHg | 8.70 (6.00–12.00) | |
| Cardiac index, L/min/m2 | 2.09 (1.68–2.58) | |
| Pulmonary vascular resistance, dyn · s · cm−5 | 945.45 (636.77–1289.90) | |
| Treatments | Frequency (%) | |
| No PAH targeted therapy | 41 (10%) | |
| Monotherapy | 134 (31%) | |
| Dual therapy | 217 (51%) | |
| Triple therapy | 37 (9%) | |
| Anticoagulation | 310 (72%) | |
| Calcium Channel Blocker | 74 (17%) | |
| Endothelin Receptor Antagonist | 247 (58%) | |
| Prostacyclin analogue | 96 (22%) | |
| PDE5 inhibitor | 329 (77%) | |
| Selexipag | 11 (3%) | |
| Riociguat | 16 (4%) | |
| Ethnicity | ||
| White | 375 (87%) | |
| Black | 8 (2%) | |
| South Asian | 16 (4%) | |
| Other ethnicity/not stated | 30 (7%) | |
PDE5 phosphodiesterase-5.